Lab Work for Endocrine/Metabolic: 36.4% of denials overturned
In 107 California IMR decisions from 2006 to 2026, reviewers overturned 39 (36.4%). In the last five years: 11.5% of 26. 18 were medical-necessity disputes, 89 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 6 | 16.7% |
| 2022 | 4 | 0.0% |
| 2023 | 6 | 0.0% |
| 2024 | 6 | 16.7% |
| 2025 | 3 | 33.3% |
| 2026 | 1 | 0.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 32 | 18.8% | 36.4% |
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 25 | 16.0% | 36.4% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 10 | 0.0% | 36.4% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 5 | 0.0% | 36.4% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The parent of a patient has requested authorization and coverage for a human growth hormone stimulation test. This patient presents with Ehlers-Danlos syndrome (EDS). The progeroid form of EDS has been associated with adult stature shorter than expected based on unaffected parents of normal height. If this patient’s height continues to track along the current percentile, the patient’s final adult …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested reimbursement for advanced lipoprotein testing. There is sufficient support in the peer-reviewed literature for the use of advanced lipoprotein testing with lipoprotein(a) (Lp(a)) for certain patients for whom the results may refine risk assessment and thereby guide treatment decisions regarding pharmacotherapy. This includes the patient in …”
“Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for advanced lipoprotein testingFindings: The physician reviewer found that based on current American Heart Association (AHA) and American College of Cardiology (ACC) prevention guidelines, this patient is not classified as a candidate for statin therapy to reduce his cardiovascular risk given his scoring (Arnett, et al.). However, his scoring supports …”
And one the reviewer upheld
“The physician reviewer found that a patient has requested reimbursement for a lipoprotein(a) test.The National Lipid Association states that lipoprotein(a) testing is reasonable to refine atherosclerotic risk in patients with first-degree relatives with premature arteriosclerotic cardiovascular disease, personal history of premature arteriosclerotic cardiovascular disease, primary severe hypercholesterolemia, or suspected familial hypercholesterolemia. Medical literature generally notes that lipoprotein(a) testing may help …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Lab Work denials for Endocrine/Metabolic overturned?
In 107 California IMR decisions from 2006 to 2026, reviewers overturned 39 (36.4%). In the last five years: 11.5% of 26. 18 were medical-necessity disputes, 89 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.